Patents Examined by Nick Zou
-
Patent number: 9249195Abstract: The present invention provides for modified reoviruses that carry ?-helical epitopes from a variety of pathogens, as well as methods of using such modified reoviruses to generate immune responses against those epitopes in hosts.Type: GrantFiled: April 4, 2011Date of Patent: February 2, 2016Assignee: Vanderbilt UniversityInventors: Terence S. Dermody, Karl W. Boehme, Mine Ikizler, Gregory J. Wilson, James D. Chappell
-
Patent number: 9234183Abstract: Described is a parvovirus, in particular a H-IPV, that can be genetically retargeted through modification of its capsid, which is useful in cancer therapy.Type: GrantFiled: April 9, 2013Date of Patent: January 12, 2016Assignee: DEUTSCHES KREBSFORSCHUNGZENTRUMInventors: Antonio Marchini, Nazim El-Andaloussi, Jean Rommelaere, Barbara Leuchs, Xavier Allaume
-
Patent number: 9193790Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.Type: GrantFiled: December 6, 2007Date of Patent: November 24, 2015Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: James Arthos, Diana Goode, Claudia Cicala, Anthony Fauci
-
Patent number: 9125870Abstract: Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype 26 that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.Type: GrantFiled: March 22, 2013Date of Patent: September 8, 2015Assignee: Crucell Holland B.V.Inventors: Katarina Radosevic, Jerome H. H. V. Custers, Jort Vellinga, Myra N. Widjojoatmodjo
-
Patent number: 9119813Abstract: Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.Type: GrantFiled: March 22, 2013Date of Patent: September 1, 2015Assignee: Crucell Holland B.V.Inventors: Katarina Radosevic, Jerome H. H. V. Custers, Jort Vellinga, Myra N. Widjojoatmodjo
-
Patent number: 9115185Abstract: The invention is concerned with epitopes derived from human papilloma virus, and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes. The invention further provides clinically relevant approaches for immunizing subjects against (Myco)bacterially and/or virally infected cells or tumor cells, and in particular against HPV. The invention demonstrates that peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, the invention demonstrates that vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The invention further demonstrates that the intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.Type: GrantFiled: February 28, 2007Date of Patent: August 25, 2015Assignee: Academisch Ziekenhuis LeidenInventors: Sjoerd Hendrikus Van Der Burg, Tom H. M. Ottenhoff, Annemieke Geluk, Maria Johanna Philomena Schoenmaekers-Welters, Annemieke M. De Jong, Rienk Offringa, Cornelis Johannes Maria Melief, Rene Everardus Maria Toes
-
Patent number: 9079943Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: GrantFiled: March 28, 2014Date of Patent: July 14, 2015Assignee: ALPHAVAX, INC.Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
-
Patent number: 9029133Abstract: The present invention provides a recombinant virus containing a nucleotide sequence encoding a tumor-therapeutic full-length antibody with human constant regions, and uses thereof. After a nucleotide sequence of a gene encoding a tumor-therapeutic full-length antibody with human constant regions of the light chain and the heavy chain is inserted into the genome of a recombinant virus, the tumor-therapeutic full-length antibody with human constant regions can be efficiently expressed in tumor cells, thereby inhibit the growth and metastasis of tumors.Type: GrantFiled: April 29, 2004Date of Patent: May 12, 2015Inventors: Qijun Qian, Qi Zhang, Qin Yang, Mengchao Wu
-
Patent number: 8992929Abstract: The present invention relates to the murine monoclonal antibody 4C2 or to chimeric or humanized monoclonal antibodies specific to a major neutralizing epitope of influenza H5 hemagglutinin and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H5N1 influenza using such murine or chimeric or humanized monoclonal antibodies or fragments thereof.Type: GrantFiled: August 23, 2010Date of Patent: March 31, 2015Assignee: Temasek Life Sciences Laboratory LimitedInventors: Prabakaran Mookkan, Fang He, Hwei-Sing Jimmy Kwang
-
Patent number: 8975378Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.Type: GrantFiled: December 24, 2009Date of Patent: March 10, 2015Assignees: Osaka University, The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Kazuyoshi Ikuta, Ritsuko Koketsu, Yoshinobu Okuno, Mikihiro Yunoki, Shoji Ideno, Masatoshi Oshita, Motoki Kuhara, Masatoshi Momota
-
Patent number: 8961978Abstract: The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.Type: GrantFiled: July 12, 2012Date of Patent: February 24, 2015Assignee: Crucell Holland B.V.Inventors: Theodorus Hendrikus Jacobus Kwaks, David Adrianus Theodorus Maria Zuijdgeest, Ronald Vogels, Robert Heinz Edward Friesen
-
Patent number: 8951534Abstract: The invention relates to therapeutic vaccines for the treatment of neoplasias caused by the human papillomavirus (HPV). In particular, the vaccines of the present invention are formed by chimeric virus-like capsids of birnavirus containing papillomavirus antigens.Type: GrantFiled: November 5, 2010Date of Patent: February 10, 2015Assignee: Chimera Pharma, S.L.UInventors: Thomas Zurcher, Cayetano Von Kobbe, Juan J. Bernal, Ignacio Jiménez Torres, Gloria Calderita Lucas, Margarita Rodriguez Garcia, Ana Garzon Gutierrez, Virginia Gondar Sousa E Silva, Arcadio García De Castro, Irene Pino De La Huerga
-
Patent number: 8900880Abstract: The present invention relates to an antigenically effective peptide comprising, from the amino to the carboxylic terminal, the amino acid sequence: G P P W W P P I C D P P Q P S K T Q G Q S X1 G Q S X2 G X3 G X4 G X5 G X6 G X7 G K G K S X8 D K Q X9 K P G G P W X10 P E P (SEQ ID No. 1), wherein the amino acids X1-X10 are selected independently from an arginine residue or a citrulline residue and at least one of X1-X10 is a citrulline residue, or a functional fragment thereof and uses thereof.Type: GrantFiled: November 22, 2010Date of Patent: December 2, 2014Assignee: Toscana Biomarkers S.R.L.Inventors: Paola Migliorini, Federico Pratesi
-
Patent number: 8889137Abstract: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.Type: GrantFiled: October 1, 2010Date of Patent: November 18, 2014Assignees: Universität Duisberg Essen, Rheinische Friedrich Wilhelms —Universität BonnInventors: Michael Roggendorf, Anna-Maria Eis-Hübinger, Jürgen Krauss, Karl Eduard Schneweis, Michaela Arndt, Adalbert Krawczyk, Evelyn Exner, Martin P. Däumer, Edelgard Schneweis
-
Patent number: 8852608Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.Type: GrantFiled: December 23, 2009Date of Patent: October 7, 2014Assignee: MedImmune, LLCInventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, Joann Suzich
-
Patent number: 8846056Abstract: Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof.Type: GrantFiled: August 4, 2010Date of Patent: September 30, 2014Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease ControlInventors: Larry J. Anderson, Lia M. Haynes, Ralph A. Tripp
-
Patent number: 8778351Abstract: The present invention relates to compositions that contain a chimeric papillomavirus virus-like particle (VLP) in combination with a DNA molecule encoding a protein or polypeptide epitope. The chimeric papillomavirus VLP is assembled from an L1 protein or polypeptide and a chimeric protein or polypeptide containing at least a portion of the L2 protein and a protein or polypeptide including an immunogenic epitope. The composition is useful for inducing an enhanced immune response against a pathogen or a tumor.Type: GrantFiled: August 30, 2007Date of Patent: July 15, 2014Assignee: University of RochesterInventors: Robert C. Rose, Christine Malboeuf, Young-Eun Ellen Lee
-
Patent number: 8771706Abstract: Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogs thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogs thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogs thereof.Type: GrantFiled: February 11, 2013Date of Patent: July 8, 2014Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Larry J. Anderson, Lia M. Haynes, Ralph A. Tripp
-
Patent number: 8765143Abstract: An immunogenic fusion protein includes at least, on the C-terminal side, a first peptide composed of the S protein deleted of the transmembrane domain thereof located at the N-terminal end thereof, of a hepatitis B virus (HBV) isolate, and on the N-terminal side, a second peptide composed of the transmembrane domain and of the ectodomain of at least one envelope protein of a hepatitis C virus (HCV) isolate. A hybrid nucleic acid molecule encoding the fusion protein, and a vector including the hybrid nucleic acid molecule, a subviral particle including the fusion protein, an immunogenic composition including at least the fusion protein, or at least the hybrid nucleic acid molecule, or at least the subviral particle, and a cell line for the production of the fusion protein, or of the hybrid nucleic acid molecule, or of the subviral particle are described.Type: GrantFiled: June 16, 2009Date of Patent: July 1, 2014Assignee: Universite Francois Rabelais de ToursInventors: Philippe Roingeard, Christophe Hourioux, Romuald Patient
-
Patent number: 8748087Abstract: The present invention provides an isolated polynucleotide acid comprising a polynucleotide sequence having a substantial amount of sequence identity to the entire length of the polynucleotide sequence as set forth in SEQ ID NO: 1 or its complementary strand (SEQ ID NO: 2), the sequence is derived from RT domain of HBV polymerase gene. The present invention also provides a polypeptide and related compositions, as well as methods for using the same.Type: GrantFiled: December 20, 2006Date of Patent: June 10, 2014Assignee: Fudan UniversityInventors: Yu-Mei Wen, Yong-Xiang Wang, Zhang-Mei Ma